Received Jul 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
had chills and nausea afterwards; nausea; pain in kidney area; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of chills in a patient who received Herpes zoster (Shingrix) for prophylaxis. On 17-JUN-2025, the patient received Shingrix. In JUN-2025, less than a week after receiving Shingrix, the patient experienced chills (Verbatim: had chills and nausea afterwards), nausea (Verbatim: nausea) and perirenal pain (Verbatim: pain in kidney area). In JUN-2025, the outcome of the chills was resolved. The outcome of the nausea and perirenal pain were not reported. It was unknown if the reporter considered the chills, nausea and perirenal pain to be related to Shingrix. It was unknown if the company considered the chills, nausea and perirenal pain to be related to Shingrix. Additional Information: GSK Receipt Date: 18-JUN-2025 This case was reported by a consumer via (shingrix GRC Chatbot) interactive digital media. The patient had the Shingrix vaccine the day before reporting, had chills and nausea afterwards. Chills were gone, but he/she had sharp pain in kidney area.